MRD Feasibility Study

Trial overview

Minimal Residual Disease monitoring in adult acute lymphoblastic leukaemia: a laboratory feasibility study.

Inclusion criteria

Patients aged between 20 and 60 years inclusive with previously untreated Philadelphia chromosome negative ALL are eligible. Patients should be registered with the Clinical Trials Service Unit (CTSU) and following treatment as defined by the UKALL XII induction protocol.

Exclusion criteria

Patients not following UKALL XII induction therapy.

Contact details

Principal Investigator

Prof. David Bowen

Tel 0113 2068481

Email david.bowen@leedsth.nhs.uk

Research Nurse

Alex Stichler

Tel 0113 2068577

Email alex.stichler@leedsth.nhs.uk

Other trials currently active for Acute Lymphoblastic Leukaemia

UKALL 2003

Please copy and paste the URL below into a new window for more information on UKALL 2003:

http://www.ctsu.ox.ac.uk/

Then go to 'Projects', 'UKALL2003' 

Tags

minimal residual disease acute lymphoblastic leukaemia feasibility study